33606-34-7

Usage

Physical state

Clear, colorless liquid

Odor

Slightly sweet

Flammability

Highly flammable

Uses

Solvent, production of polymers and resins, synthesis of pharmaceuticals, pharmaceutical intermediate

Safety precautions

Avoid contact with skin and eyes, may cause irritation and harm.

Upstream product

• 35942-95-1 2-(furan-2-yl)ethanol 
• 126502-98-5 3-hydroxy-6-bromohexanoic acid 
• 629-11-8 1,6-hexanediol 
• 2434-02-8 ethyl tetrahydrofuran-2-acetate 
• 123433-61-4 4-(3-Benzyloxy-propyl)-3-trimethylsilanyl-oxetan-2-one 
• 123433-56-7 4-(3-Benzyloxy-propyl)-oxetan-2-one 
• 123433-58-9 (Tetrahydro-furan-2-yl)-acetic acid benzyl ester 

Downstream Products

• 2434-00-6 (tetrahydro-furan-2-yl)-acetic acid 
• 888741-17-1 ethyl 3-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-isopropoxyphenyl]propanoate 
• 895244-33-4 2-tetrahydrofuran-2-ylethyl 4-methylbenzenesulfonate 
• 1050493-67-8 2-(2-bromoethyl)oxolane 

Relevant academic research and scientific papers

An Intramolecular Iodine-Catalyzed C(sp3)?H Oxidation as a Versatile Tool for the Synthesis of Tetrahydrofurans

The formation of ubiquitous occurring tetrahydrofuran patterns has been extensively investigated in the 1960s as it was one of the first examples of a non-directed remote C?H activation. These approaches suffer from the use of toxic transition metals in overstoichiometric amounts. An attractive metal-free solution for transforming carbon-hydrogen bonds into carbon-oxygen bonds lies in applying economically and ecologically favorable iodine reagents. The presented method involves an intertwined catalytic cycle of a radical chain reaction and an iodine(I/III) redox couple by selectively activating a remote C(sp3)?H bond under visible-light irradiation. The reaction proceeds under mild reaction conditions, is operationally simple and tolerates many functional groups giving fast and easy access to different substituted tetrahydrofurans.

PIKFYVE KINASE INHIBITORS

The present invention relates to compounds useful as inhibitors of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) as well as their use for treating diseases and disorders associated with PIKfyve.

TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS

The present invention relates to methods of treating viral infections including COVID-19 and compositions with a combination of (i) an inhibitor of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) and (ii) an inhibitor of transmembrane serine proteinase 2 (TMPRSS-2).

Sulfamyl Radicals Direct Photoredox-Mediated Giese Reactions at Unactivated C(3)-H Bonds

Alcohol-anchored sulfamate esters guide the alkylation of tertiary and secondary aliphatic C(3)-H bonds. The transformation proceeds directly from N-H bonds with a catalytic oxidant, a contrast to prior methods which have required preoxidation of the reactive nitrogen center, or employed stoichiometric amounts of strong oxidants to obtain the sulfamyl radical. These sulfamyl radicals template otherwise rare 1,6-hydrogen-atom transfer (HAT) processes via seven-membered ring transition states to enable C(3)-H functionalization during Giese reactions.

PIKFYVE KINASE INHIBITORS

The present invention relates to compounds of formula (I) (shown below) useful as inhibitors of phosphatidylinositol- 3 -phosphate 5-kinase (PIKfyve) as well as their use for treating diseases and disorders associated with PIKfyve.

TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES AS INHIBITORS OF HBSAG (HBV SURFACE ANTIGEN) AND HBV DNA PRODUCTION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS

The present invention provides tetrahydropyridopyrimidines and tetrahydropyridopyridines having the general formula (I) wherein R1, R2, U, W, X, Y and Z are as described herein, as inhibitors of HBsAg (HBV surface antigen) and HBV DNA production for the treatment and prophylaxis of hepatitis B virus infections.

Polynucleotides encoding enantioselective carboxylesterases and methods of making same

The present invention relates to a polynucleotide encoding an enzyme having carboxylesterase [E.C.3.1.1.1] activity.

CONDENSED TRICLYCLIC COMPOUNDS AS INHIBITORS OF HIV REPLICATION

Compounds of formula (I) and pharmaceutical compositions thereof: wherein A1 A2 and A3 are each independently selected from the group consisting of N and CR3, wherein R1 is an optionally substituted heterocyclyl or an optionally substituted -(C1-6)alkyl-heterocyclyl, R2 is an optionally substituted aryl or an optionally subsisted heteroaryl, R4 is an optionally substituted aryl, an optionally substituted heterocyclyl or an optionally substituted heteroaryl, useful as an inbitor of HIV replication.

INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF

The present invention relates to a novel indazole- or pyrrolopyridine-derivative, represented by the formula (1) below, that has an agonistic action or a partial agonistic action against serotonin-4 receptor, and a pharmaceutical composition comprising the same. Formula (1) [wherein each substituent is as defined in claim 1]

IMIDAZOLE DERIVATIVES AS IDO INHIBITORS

Presently provided are IDO inhibitors of general formulae (VII), (VIII) as shown below and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.